OverviewSuggest Edit

Translate Bio develops medicines to treat diseases caused by protein or gene dysfunction. It uses single-stranded oligonucleotides to target the repressive interactions of long non-coding RNA (lncRNA) with specific genes of interest, thereby upregulating mRNA and increasing expression of the encoded protein. The Company is applying its proprietary technology to develop new treatments in several therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, oncology, metabolic diseases and neurodegenerative diseases.
TypePublic
Founded2011
HQLexington, MA, US
Websitetranslate.bio

Latest Updates

Employees (est.) (Dec 2018)81(+33%)
Revenue (FY, 2019)$7.8 M(+450%)
Share Price (Jan 2021)$23.3
Cybersecurity ratingDMore

Key People/Management at Translate Bio

Ronald C. Renaud

Ronald C. Renaud

CEO & Director
John Schroer

John Schroer

CFO
Ann Barbier

Ann Barbier

Chief Medical Officer
Paul Burgess

Paul Burgess

Chief Legal Officer and Chief Operating Officer
Brian Fenton

Brian Fenton

Chief Business Officer
Paula Cloghessy

Paula Cloghessy

Chief People Officer
Show more

Translate Bio Office Locations

Translate Bio has an office in Lexington
Lexington, MA, US (HQ)
29 Hartwell Ave
Show all (1)

Translate Bio Financials and Metrics

Translate Bio Revenue

Translate Bio's revenue was reported to be $7.80 m in FY, 2019
USD

Revenue (Q3, 2020)

66.4m

Net income (Q3, 2020)

17.3m

EBIT (Q3, 2020)

16.7m

Market capitalization (15-Jan-2021)

1.7b

Closing stock price (15-Jan-2021)

23.3

Cash (30-Sept-2020)

674.1m

EV

1.1b
Translate Bio's current market capitalization is $1.7 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.4m7.8m

General and administrative expense

11.1m14.3m22.6m28.6m

R&D expense

15.7m47.0m58.0m76.4m

Operating expense total

26.8m79.2m80.6m105.0m
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

238.0k1.5m1.2m1.3m4.7m16.3m66.4m

General and administrative expense

3.0m4.8m6.0m6.0m6.6m7.9m6.9m7.5m8.6m9.2m

R&D expense

9.6m12.7m15.2m12.9m17.4m16.6m17.3m21.4m29.0m26.3m

Operating expense total

14.9m22.4m21.2m18.9m24.0m24.5m24.2m28.9m37.6m35.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

57.7m48.1m55.2m84.6m

Prepaid Expenses

685.0k3.0m4.5m9.4m

Current Assets

205.6m198.5m149.6m203.6m

PP&E

4.9m6.8m10.2m12.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

30.8m16.5m38.9m62.4m74.9m98.9m97.5m272.2m674.1m

Prepaid Expenses

4.3m4.8m4.2m5.2m6.1m6.6m6.9m7.9m10.8m

Current Assets

182.8m24.3m166.3m128.9m153.9m217.8m169.2m316.2m711.0m

PP&E

9.2m9.9m10.1m10.8m10.9m10.7m13.8m15.2m15.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(26.7m)(66.4m)(97.4m)(113.3m)

Depreciation and Amortization

730.0k1.6m2.8m4.7m

Accounts Payable

84.0k4.0m658.0k9.9m

Cash From Operating Activities

(23.7m)(50.8m)(22.1m)(82.2m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(14.0m)(21.2m)(48.7m)(91.4m)(33.2m)(61.0m)(82.3m)(14.3m)(33.2m)

Depreciation and Amortization

191.0k536.0k1.4m1.9m1.0m2.0m3.0m1.4m5.6m6.4m

Accounts Payable

698.0k1.5m1.1m(1.6m)(1.0m)(1.9m)(1.7m)(9.5m)(2.8m)(8.6m)

Cash From Operating Activities

(9.6m)(16.9m)(33.6m)(5.9m)(21.5m)(41.4m)(61.9m)(31.4m)(51.5m)258.3m
USDFY, 2016

Financial Leverage

-5.3 x
Show all financial metrics

Translate Bio Acquisitions / Subsidiaries

Company NameDateDeal Size
Translate Bio MA
Translate Bio Securities Corporation

Translate Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

D

65/100

SecurityScorecard logo

Translate Bio Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Translate Bio Online and Social Media Presence

Embed Graph

Translate Bio News and Updates

Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021

-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- -- Completed enrollment and dosing for upcoming second interim data analysis; includes 8, 12 and 16 mg multiple…

Translate Bio Announces Departure of Chief Financial Officer

LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced today that John Schro…

Translate Bio Announces Third Quarter 2020 Financial Results and Reviews Recent Progress

-- Advances Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) with resumption of COVID-impacted enrollment and dosing -- -- Presented promising preclinical data at NACFC from next-generation CF program that leverages advances in mRNA technology --

Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies

Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies

Translate Bio Resumes Enrollment and Dosing in Phase 1/2 Clinical Trial of MRT5005 in Cystic Fibrosis

LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that enrollment and …

Thinking about buying stock in Trevena, Translate Bio, Workhorse Group, Dynavax Technologies, or Seelos Therapeutics?

NEW YORK, June 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRVN, TBIO, WKHS, DVAX, and SEEL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Translate Bio Frequently Asked Questions

  • When was Translate Bio founded?

    Translate Bio was founded in 2011.

  • Who are Translate Bio key executives?

    Translate Bio's key executives are Ronald C. Renaud, John Schroer and Ann Barbier.

  • How many employees does Translate Bio have?

    Translate Bio has 81 employees.

  • What is Translate Bio revenue?

    Latest Translate Bio annual revenue is $7.8 m.

  • What is Translate Bio revenue per employee?

    Latest Translate Bio revenue per employee is $96.3 k.

  • Who are Translate Bio competitors?

    Competitors of Translate Bio include Biosynex, EXACT Sciences and HeMemics Biotechnologies.

  • Where is Translate Bio headquarters?

    Translate Bio headquarters is located at 29 Hartwell Ave, Lexington.

  • Where are Translate Bio offices?

    Translate Bio has an office in Lexington.

  • How many offices does Translate Bio have?

    Translate Bio has 1 office.